Atlas Trials

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Clinical trial NCT00615940 · COMPLETED

Trial details

NCT number
NCT00615940
Sponsor
Heidelberg Pharma AG
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2008-07-01
Primary completion
2011-12-01
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.